Ozempic

Ozempic

semaglutide

Manufacturer:

Novo Nordisk

Distributor:

Zuellig Pharma

Marketer:

Novo Nordisk
Concise Prescribing Info
Contents
Semaglutide
Indications/Uses
Adjunct to diet & exercise in adults w/ insufficiently controlled type 2 DM as monotherapy when metformin is inappropriate due to intolerance or CI; in addition to other medicinal products. Reduce risk of major adverse CV events (CV death, non-fatal MI or stroke) in adult w/ type 2 DM & established CV disease.
Dosage/Direction for Use
SC Initially 0.25 mg once wkly. Increased dose to 0.5 mg once wkly after 4 wk then, further increased to 1 mg once wkly after at least 4 wk to further improve glycaemic control.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Not to be used in patients w/ type 1 DM or for treatment of diabetic ketoacidosis. Not a substitute for insulin. Discontinue if pancreatitis is suspected. Patients w/ CHF NYHA Class IV. History of acute pancreatitis. Increased risk of hypoglycaemia; diabetic retinopathy complications. Closely monitor patients w/ diabetic retinopathy treated w/ insulin. May affect ability to drive & use machines when used in combination w/ sulfonylurea or insulin. Severe renal & hepatic impairment. Not recommended in patients w/ end-stage renal disease. Women of childbearing potential should use contraception. Discontinue at least 2 mth before planned pregnancy. Not to be used during pregnancy & lactation. Childn & adolescents <18 yr. Elderly ≥75 yr.
Adverse Reactions
Hypoglycaemia when used w/ insulin or sulfonylurea; nausea, diarrhoea. Hypoglycaemia (when used w/ other oral antidiabetics), decreased appetite; dizziness, diabetic retinopathy complications; vomiting, abdominal pain & distension, constipation, dyspepsia, gastritis, GERD, eructation, flatulence; cholelithiasis; fatigue; increased lipase & amylase, decreased wt.
Drug Interactions
Decreased AUC & Cmax of paracetamol. Increased exposure of levonorgestrel at steady state. Warfarin & other coumarin derivatives.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BJ06 - semaglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Ozempic soln for inj 0.25 mg
Packing/Price
1's
Form
Ozempic soln for inj 0.5 mg
Packing/Price
1's
Form
Ozempic soln for inj 1 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in